Protein Binding of Lopinavir and Ritonavir During 4 Phases of Pregnancy
- 1 May 2013
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 63 (1) , 51-58
Abstract
Objective: To investigate the intraindividual pharmacokinetics (PKs) of total (protein bound plus unbound) and unbound lopinavir/ritonavir (LPV/RTV) and to assess whether the pediatric formulation (100 mg/25 mg) can overcome any pregnancy-associated changes. Design: Prospective longitudinal PK study. Methods: HIV-infected pregnant antiretroviral therapy–naive and experienced women receiving LPV/RTV 400 mg/100 mg tablets twice daily. Intensive PK evaluations were performed at 20–24 weeks (PK1), 30 weeks (PK2) followed by empiric dose increase using the pediatric formulation (100 mg/25 mg twice daily), 32 weeks (PK3), and 8 weeks postpartum (PK4). Results: Twelve women completed prespecified PK evaluations. Median (range) age was 28 (18–35) years and baseline BMI was 32 (19–41) kg/m2. During pregnancy, total area under the time concentration (AUC0–12h) for LPV was significantly lower than postpartum (PK1, PK2, or PK3 vs. PK4, P = 0.005). Protein-unbound LPV AUC0–12h remained unchanged during pregnancy [PK1: 1.6 (1.3–1.9) vs. PK2: 1.6 (1.3–1.9) μg·h/mL, P = 0.4] despite a 25% dose increase [PK2 vs. PK3: 1.8 (1.3–2.1) μg·h/mL, P = 0.5]. Protein-unbound LPV predose concentrations (C12h) did not significantly change despite dose increase [PK2: 0.10 (0.08–0.15) vs. PK3: 0.12 (0.10–0.15) μg/mL, P = 0.09]. Albumin and LPV AUC0–12h fraction unbound were correlated (rs = 0.3, P = 0.03). Conclusions: Total LPV exposure was significantly decreased throughout pregnancy despite the increased dose. However, the exposure of unbound LPV did not change significantly regardless of trimester or dose. Predose concentrations of unbound LPV were not affected by the additional dose and were 70-fold greater than the minimum efficacy concentration. These findings suggest dose adjustments may not be necessary in all HIV-infected pregnant women.Keywords
This publication has 28 references indexed in Scilit:
- Improved Oral Bioavailability of Lopinavir in Melt-Extruded Tablet Formulation Reduces Impact of Third Trimester on Lopinavir Plasma ConcentrationsAntimicrobial Agents and Chemotherapy, 2012
- Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and RitonavirAntimicrobial Agents and Chemotherapy, 2004
- Lopinavir Protein Binding In Vivo Through the 12-Hour Dosing IntervalTherapeutic Drug Monitoring, 2004
- Pharmacokinetics of Antiretrovirals in Pregnant WomenClinical Pharmacokinetics, 2004
- Protein Binding in Antiretroviral TherapiesAIDS Research and Human Retroviruses, 2003
- Human Immunodeficiency Virus Type 1 Genotypic and Pharmacokinetic Determinants of the Virological Response to Lopinavir-Ritonavir-Containing Therapy in Protease Inhibitor-Experienced PatientsAntimicrobial Agents and Chemotherapy, 2002
- Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United StatesRevised November 3, 2000HIV Research & Clinical Practice, 2001
- ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week resultsAIDS, 2001
- HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡Drug Metabolism Reviews, 2001
- Liquid chromatographic determination of urinary 6β-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant womenJournal of Pharmaceutical and Biomedical Analysis, 2000